Factor XI(a) Inhibition in Secondary Stroke Prevention: On the Cusp of a New Anticoagulation Paradigm. (PubMed, ACS Pharmacol Transl Sci) - Oct 9, 2026 - "Current FXI-targeted approaches include oral small-molecule FXIa inhibitors (asundexian and milvexian), antisense oligonucleotides (fesomersen), and monoclonal antibodies (abelacimab and osocimab). In contrast, OCEANIC-AF showed inferior efficacy compared with apixaban in atrial fibrillation, suggesting that the therapeutic value of FXIa inhibition is strongly dependent on clinical context. Taken together, this review summarizes the pathophysiological rationale, pharmacology, and clinical evidence supporting FXI inhibition for secondary ischemic stroke prevention and discusses future precision-medicine strategies for patient selection."
Journal • Atrial Fibrillation • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Hematological Disorders • Ischemic stroke • Thrombosis
|